The cost utility of solifenacin in the treatment of overactive bladder

Overactive bladder may cause significant discomfort to patients. The standard therapy for overactive bladder includes behavioural therapy and sometimes medication. Recently, a new medication (solifenacin 5 and 10 mg) was developed for treatment of overactive bladder. The objective of this study was to assess the cost utility of solifenacin 5 and 10 mg for overactive bladder. We developed a Markov model to estimate the cost per quality adjusted life years (QALY) over a period of 12-months. Model parameters were based on randomized clinical trials for solifenacin 5 and 10 mg. Data on utility scores were taken from the literature. The incremental cost per QALY for solifenacin 5 mg and solifenacin 10 mg compared with placebo were A 17,602 pound and A 24,464 pound respectively. Sensitivity analyses showed that these results were robust to changes of relevant input data. Solifenacin 5 and 10 mg are cost-effective treatments in patients with overactive bladder.